Real-World Sequencing Patterns of BCMA-Directed Therapies in Relapsed/Refractory Multiple Myeloma

Dr. Mansi Shah presents a multinational real-world analysis evaluating how BCMA-directed CAR-T cell therapies and BCMA bispecific antibodies are being used in routine clinical practice for patients with relapsed/refractory multiple myeloma (R/R MM). She reviews the retrospective study design and summarizes treatment patterns across multiple countries, demonstrating that CAR-T therapy is more frequently selected for younger, fitter patients, whereas BCMA bispecific antibodies are more commonly used in older patients or those with greater comorbidity. The analysis also highlights evolving use of these therapies in earlier lines of treatment and explores sequencing patterns among patients who received a bispecific antibody following prior CAR-T therapy. The study findings underscore that real-world treatment decisions are driven by patient fitness, access, logistics, and treatment availability rather than direct comparisons of efficacy, emphasizing the continued need for prospective evidence to define optimal sequencing strategies for BCMA-directed therapies in relapsed/refractory multiple myeloma.